Drugs in Dev.
Hepatology (Liver, Pancreatic, Gall Bladder)
IND Enabling
Singapore 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership
Details : Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $1,000.0 million
January 09, 2020
Lead Product(s) : Enx108A
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1,000.0 million
Deal Type : Partnership
